Literature DB >> 25821649

Adapting SugarWatch to manage metabolic syndrome in a partial hospitalization program: a feasibility study.

Renee W Latimer1, Rose Clute1.   

Abstract

A successful worksite diabetes prevention program, SugarWatch,was adapted for a seriously mentally ill patient population in a partial hospitalization program in Hawai'i. A feasibility study was implemented using an intervention with 3 components: SugarWatch curriculum, structured physical activity,and Create a Plate lunch. Twenty participants completed the three month intervention. Only systolic blood pressure showed statistically significant improvement. However, trends in improvement were also seen with diastolic blood pressure and total cholesterol. Despite minimal improvement in physiological measures, the project changed practice in the setting to align with the 2004 American Diabetes Association and American Psychiatric Association Guidelines for the prevention of metabolic syndrome and better management of patients taking second generation antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25821649      PMCID: PMC4363928     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN: 2165-8242


  11 in total

1.  Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study.

Authors:  R G McCreadie
Journal:  Br J Psychiatry       Date:  2003-12       Impact factor: 9.319

Review 2.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

3.  Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

Authors:  Jeffrey A Lieberman
Journal:  Arch Gen Psychiatry       Date:  2006-10

Review 4.  Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

Authors:  Mario Alvarez-Jiménez; Sarah E Hetrick; César González-Blanch; John F Gleeson; Patrick D McGorry
Journal:  Br J Psychiatry       Date:  2008-08       Impact factor: 9.319

5.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

Review 6.  Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Authors:  S M Stahl; L Mignon; J M Meyer
Journal:  Acta Psychiatr Scand       Date:  2009-03       Impact factor: 6.392

Review 7.  Obesity in patients with severe mental illness: overview and management.

Authors:  Susan L McElroy
Journal:  J Clin Psychiatry       Date:  2009       Impact factor: 4.384

8.  Primary care issues in patients with mental illness.

Authors:  Bernadette Kiraly; Karen Gunning; Jennifer Leiser
Journal:  Am Fam Physician       Date:  2008-08-01       Impact factor: 3.292

Review 9.  Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Elena Bonfioli; Loretta Berti; Claudia Goss; Francesca Muraro; Lorenzo Burti
Journal:  BMC Psychiatry       Date:  2012-07-12       Impact factor: 3.630

10.  Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Authors:  Elaine H Morrato; John W Newcomer; Siddhesh Kamat; Onur Baser; James Harnett; Brian Cuffel
Journal:  Diabetes Care       Date:  2009-02-24       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.